Webcast

What’s Your Protocol? Streamlining Oncology/Pathology Collaboration Throughout the BC Journey

Launch Date
04/23/2026
Credit Amount
1.25
Credit Expires
04/23/2027

Faculty

Zena Jameel, MD
Interim Director of Breast Pathology and Associate Member
Director of Oncologic Surgical Pathology Fellowship
Moffitt Cancer Center
Associate Professor, University of South Florida
Tampa, FL
Lucio N. Gordan, MD
President/Managing Physician
Chair of the Executive Board
Florida Cancer Specialists & Research Institute
Gainesville, FL
Janet McNaughton, MD
Associate Pathologist
Florida Cancer Center
Fort Myers, FL
Hatem Soliman, MD
Senior Member, Departments of Breast and Immunology
Medical Director, Clinical Trials Office
Moffitt Cancer Center and Research Institute
Professor, Department of Oncologic Sciences
College of Medicine, University of South Florida
Tampa, FL
Amanda Warner, MS, RN, OCN
Director, Real-World Evidence
Florida Cancer Specialists & Research Institute, LLC
Cape Coral, FL
Xiaoxian (Bill) Li, MD, PhD
Professor of Pathology
Department of Pathology and Laboratory Medicine
Emory School of Medicine
Atlanta, GA
Jane L. Meisel, MD, FASCO
Moderator
Professor of Hematology and Medical Oncology
Co-Director, Breast Medical Oncology
Associate Vice-Chair of Faculty Development and Promotions
Winship Cancer Institute at Emory University
Atlanta, GA
Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

As HER2-low and ultralow classifications reshape metastatic breast cancer (mBC) treatment pathways, many practices still face real-world barriers to accurate testing and timely reporting. Intra-laboratory variability, limited uptake of emerging assays, and fragmented communication across care teams can all lead to missed opportunities for patients who may benefit from targeted therapy. Education is urgently needed to bridge gaps in practice, going beyond current standards to highlight practical strategies for reducing variability in HER2 testing and interpretation and strengthening interdisciplinary collaboration.

In the second activity of this EfficientCME webcast series, oncologist-pathologist faculty pairs present real-world examples from their own institutions that highlight how to apply current HER2 immunohistochemistry scoring guidelines and incorporate emerging assays into routine practice. Learners will discover strategies to strengthen communication and decision-making across the multidisciplinary care team, ensuring more accurate reporting, efficient treatment planning, and ultimately, better outcomes for patients living with mBC.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Employ current guidelines and expert recommendations for HER2 IHC scoring and other emerging assays to accurately identify patients with HER2-low/ultra-low mBC who may benefit from targeted therapy
  • Facilitate enhanced communication and collaboration among pathologists, oncologists, and other members of the cancer care team to improve timely and accurate reporting of individual patient and tumor HER2 status

Financial Support

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Target Audience

Medical oncologists and pathologists

Credit Information

Jointly Accredited Provider

In support of improving patient care, this activity has been planned and implemented by CME Outfitters, LLC, and EfficientCME. CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 1.25

CME Outfitters, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

Physician Associates (AAPA): 1.25

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 04/23/2027. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.25

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABPath

This activity meets the requirements and has been registered to offer credit for the American Board of Pathology for lifelong learning (CME.)

Canadian Physicians who wish to claim credit must select both ACCME and MOC certificates.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Jameel reports no financial relationships to disclose.

Dr. Gordan reports the following financial relationships:

Other financial or material support: Discloses Equity Ownership and Board of Directors member, CORE Ventures (McKesson-controlled entity)

Dr. Li reports the following financial relationships:

Advisory Board: Lilly and Roche

Consultant: Cancer Expert Now, LLC

Research Support: Champions Oncology, Inc.

Dr. Meisel reports the following financial relationships:

Advisory Board: AstraZeneca; Olema Oncology; Pfizer Inc.; and Sermonix Pharmaceuticals

Consultant: AstraZeneca; Genentech, Inc.; GSK; Novartis Pharmaceuticals Corporation; Olema Oncology; Pfizer Inc.; and Sermonix Pharmaceuticals

Research Support: AstraZeneca; Olema Oncology; and Sermonix Pharmaceuticals

Dr. McNaughton reports no financial relationships to disclose.

Dr. Soliman reports the following financial relationships:

Advisory Board: AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; and Pfizer Inc./Arvinas

Ms. Warner reports no financial relationships to disclose.

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
Sarah Hertich (Planning Committee)
Taylor Wallace (Planning Committee)
Chloe Billings, MS (Planning Committee)
Brian Moss (Planning Committee)
Jessica Rucki (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

WCV-114-042325-90

What’s Your Protocol? Streamlining Oncology/Pathology Collaboration Throughout the BC Journey
Event Date: 04/23/2026
Begin